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Reply from the Authors
Thank you for calling our attention to the importance
of anion exchange of chloride for short-chain fatty acid
anions (SSFAA) as a potential mechanism of sevelamer-
induced metabolic acidosis. To the best of our knowl-
edge, no data have been published regarding the relative
binding affinity of sevelamer hydrochloride (a quater-
nary amine anion exchange resin) for the various an-
ions present in the intestinal lumen (phosphates, sulfates,
bicarbonate, carbonate, citrate, bile acids, acetate, and
other SSFAA). However, it seems likely that binding
of SSFAA by sevelamer in the large intestine may well
be a major factor in the genesis of sevelamer-induced
metabolic acidosis, as you suggest. Final equilibration in
the gut with binding of SSFAA, bicarbonate, and bile
acids to the sevelamer resin, resulting in displacement of
phosphate, may also help to explain the well known dis-
crepancy between the in vitro and in vivo phosphate bind-
ing efficacy of sevelamer. In dialysis patients with refrac-
tory hyperphosphatemia, it has been recommended that
sevelamer and calcium acetate or calcium carbonate be
used concomitantly [1]. However, it is theoretically pos-
sible that simultaneous use of calcium-based phosphate
binders containing acetate or carbonate could further re-
duce the phosphate-binding efficacy of sevelamer. These
considerations suggest that an optimal strategy may be to
alternate use of sevelamer and calcium-based phosphate
binders with different meals during the day. Moreover, if
sodium bicarbonate supplements are needed to maintain
serum bicarbonate above 22 mEq/L, as recommended
by K/DOQI guidelines [2], the oral bicarbonate supple-
ment should probably not be ingested at the same time
as sevelamer to avoid competition between bicarbonate
and phosphate for binding to the resin.
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Kidney function itself, and not
cystatin C, is correlated with
height and weight
To the Editor: In a recent issue of this journal [1],
Knight et al presented data from a large population study
on factors influencing serum cystatin C concentrations in
adults. After adjustment for uncorrected creatinine clear-
ance (in mL/min), multivariate linear regression analysis
yielded a significant positive correlation of cystatin C with
age, male gender, weight, height, cigarette smoking, and
C-reactive protein (CRP) levels.
Traditionally, glomerular filtration rate (GFR) is nor-
malized to 1.73m2 body surface area (BSA) [2], which
is of particular importance in growing subjects. There-
fore, almost all papers correlating cystatin C with a gold-
standard GFR were indexed to BSA. When looked at,
anthropomorphometric data did not influence the cor-
relation between GFR normalized for BSA and serum
cystatin C [3].
It is therefore not surprising that Knight et al [1] identi-
fied height and weight—the chief determinants of BSA—
as confounding variables for both cystatin C and creati-
nine when studying correlation with uncorrected GFR.
It would be interesting to see which effect normalization
of creatinine clearance to BSA has on the other correla-
tions reported. Their large cohort is certainly particularly
well suited to identify factors weakly influencing serum
cystatin C concentration that have been missed so far.
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